To determine whether NF1 loss limits the efficacy of anti-HER2 therapy, we depleted NF1 expression in a panel of HER2 + breast cancer cell lines using either short hairpin (sh) RNAs or CRISPR/Cas9 (Fig. S2a, b). Here, ERBB2 is linked to breast carcinoma.